Association between plasma bilirubin and mortality
Language English Country Mexico Media print-electronic
Document type Journal Article, Observational Study, Research Support, Non-U.S. Gov't
PubMed
31054979
DOI
10.1016/j.aohep.2019.02.001
PII: S1665-2681(19)30023-7
Knihovny.cz E-resources
- Keywords
- Cancer, Cardiovascular diseases, UGT1A1,
- MeSH
- Bilirubin blood MeSH
- Biomarkers blood MeSH
- Time Factors MeSH
- Glucuronosyltransferase genetics MeSH
- Risk Assessment MeSH
- Cardiovascular Diseases blood diagnosis genetics mortality MeSH
- Middle Aged MeSH
- Humans MeSH
- Mendelian Randomization Analysis MeSH
- Neoplasms blood diagnosis genetics mortality MeSH
- Polymorphism, Genetic MeSH
- Predictive Value of Tests MeSH
- Cause of Death MeSH
- Prognosis MeSH
- Promoter Regions, Genetic MeSH
- Risk Factors MeSH
- Aged MeSH
- Sex Factors MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Poland epidemiology MeSH
- Names of Substances
- Bilirubin MeSH
- Biomarkers MeSH
- Glucuronosyltransferase MeSH
- UGT1A1 enzyme MeSH Browser
INTRODUCTION AND AIM: It has been proposed that plasma concentration of bilirubin, an endogenous antioxidant, is protective against diseases mediated by increased oxidative stress, including cardiovascular diseases (CVD) and cancer. To examine this hypothesis, we investigated the relationship between plasma bilirubin concentrations and bilirubin UDP-glucuronosyl transferase (UGT1A1) promoter gene variations (associated with increased bilirubin concentrations) with total/CVD and cancer mortality. MATERIALS AND METHODS: A nested case-control study was conducted within the Polish arm of the HAPIEE cohort. At baseline in 2002-2005, participants were examined in detail. Mortality follow-up (median (IQR) between blood draw and death was 3.7 (2.1-5.1) years) was performed by linkage with regional and national death registers. Plasma biomarkers were analysed in all subjects who died from any cause (cases, n=447) and in a random subsample of survivors (controls, n=1423). RESULTS: There was a strong negative association between plasma bilirubin levels and total and cancer mortality, expressed more profoundly in men. The adjusted OR of deaths from all causes and cancer, comparing the highest vs. lowest plasma bilirubin categories were 0.61 (95% CI: 0.42-0.87) and 0.39 (0.24-0.65), respectively. There was no association of bilirubin with CVD mortality. The UGT1A1*28 allele, a genetic marker of raised bilirubin, was also negatively associated with total/cancer mortality, although the associations were not statistically significant. DISCUSSION: Both the observational and genetic associations support the negative relationship between bilirubin and total mortality; this association appears to be driven by cancer mortality, while that with CVD mortality is not evident.
4th Department of Internal Medicine 1st Faculty of Medicine Charles University Prague Czech Republic
Department of Epidemiology and Public Health University College of London UK
References provided by Crossref.org